Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Hale O, Patterson K, Lai Y, Meng Y, Li H, Godwin JL, Homet Moreno B, Mamtani R. Hale O, et al. Among authors: patterson k. Clin Genitourin Cancer. 2021 Feb;19(1):e17-e30. doi: 10.1016/j.clgc.2020.07.006. Epub 2020 Jul 16. Clin Genitourin Cancer. 2021. PMID: 32826180 Free article.
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England.
Lee D, Amadi A, Sabater J, Ellis J, Johnson H, Kotapati S, McNamara S, Walker A, Cooper M, Patterson K, Roskell N, Meng Y. Lee D, et al. Among authors: patterson k. Pharmacoecon Open. 2019 Mar;3(1):43-54. doi: 10.1007/s41669-018-0080-5. Pharmacoecon Open. 2019. PMID: 29790020 Free PMC article.
Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England.
Lee D, Amadi A, Sabater J, Ellis J, Johnson H, Kotapati S, McNamara S, Walker A, Cooper M, Patterson K, Roskell N, Meng Y. Lee D, et al. Among authors: patterson k. Pharmacoecon Open. 2019 Mar;3(1):127. doi: 10.1007/s41669-018-0096-x. Pharmacoecon Open. 2019. PMID: 30206825 Free PMC article.
Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers.
Arora A, Abdel-Fatah TM, Agarwal D, Doherty R, Croteau DL, Moseley PM, Hameed K, Green A, Aleskandarany MA, Rakha EA, Patterson K, Ball G, Chan SY, Ellis IO, Bohr VA, Bryant HE, Madhusudan S. Arora A, et al. Among authors: patterson k. Carcinogenesis. 2016 Jan;37(1):63-71. doi: 10.1093/carcin/bgv163. Epub 2015 Nov 19. Carcinogenesis. 2016. PMID: 26586793 Free PMC article.
Human CDK18 promotes replication stress signaling and genome stability.
Barone G, Staples CJ, Ganesh A, Patterson KW, Bryne DP, Myers KN, Patil AA, Eyers CE, Maslen S, Skehel JM, Eyers PA, Collis SJ. Barone G, et al. Nucleic Acids Res. 2016 Oct 14;44(18):8772-8785. doi: 10.1093/nar/gkw615. Epub 2016 Jul 5. Nucleic Acids Res. 2016. PMID: 27382066 Free PMC article.
Assessing Clinical Improvement of Infants Hospitalized for Respiratory Syncytial Virus-Related Critical Illness.
Leland SB, Zambrano LD, Staffa SJ, McNamara ER, Newhams MM, Halasa N, Amarin JZ, Stewart LS, Shein SL, Carroll CL, Fitzgerald JC, Michaels MG, Bline K, Cullimore ML, Loftis L, Montgomery VL, Jeyapalan AS, Pannaraj PS, Schwarz AJ, Cvijanovich NZ, Zinter MS, Maddux AB, Bembea MM, Irby K, Zerr DM, Kuebler JD, Babbitt CJ, Gaspers MG, Nofziger RA, Kong M, Coates BM, Schuster JE, Gertz SJ, Mack EH, White BR, Harvey H, Hobbs CV, Dapul H, Butler AD, Bradford TT, Rowan CM, Wellnitz K, Staat MA, Aguiar CL, Hymes SR, Campbell AP, Randolph AG; RSV-PIC Investigators. Leland SB, et al. J Infect Dis. 2025 Jan 15:jiaf018. doi: 10.1093/infdis/jiaf018. Online ahead of print. J Infect Dis. 2025. PMID: 39812486
1,161 results